Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Income from Non-Controlling Interests: 2017-2024

Historic Income from Non-Controlling Interests for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to -$7.6 million.

  • BridgeBio Pharma's Income from Non-Controlling Interests rose 0.90% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.6 million, marking a year-over-year decrease of 15.46%. This contributed to the annual value of -$7.6 million for FY2024, which is 24.52% up from last year.
  • BridgeBio Pharma's Income from Non-Controlling Interests amounted to -$7.6 million in FY2024, which was up 24.52% from -$10.0 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Income from Non-Controlling Interests registered a high of -$3.5 million during FY2022, and its lowest value of -$56.8 million during FY2020.
  • Its 3-year average for Income from Non-Controlling Interests is -$7.0 million, with a median of -$7.6 million in 2024.
  • As far as peak fluctuations go, BridgeBio Pharma's Income from Non-Controlling Interests surged by 85.49% in 2022, and later slumped by 189.68% in 2023.
  • Yearly analysis of 5 years shows BridgeBio Pharma's Income from Non-Controlling Interests stood at -$56.8 million in 2020, then spiked by 57.87% to -$23.9 million in 2021, then spiked by 85.49% to -$3.5 million in 2022, then plummeted by 189.68% to -$10.0 million in 2023, then increased by 24.52% to -$7.6 million in 2024.